Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Expectations By $0.17 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) released its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17), Briefing.com reports. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The business had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same quarter in the prior year, the business posted ($0.20) earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% on a year-over-year basis.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded down $0.17 on Wednesday, reaching $23.09. 35,575 shares of the company were exchanged, compared to its average volume of 410,974. Kiniksa Pharmaceuticals has a 1 year low of $14.12 and a 1 year high of $28.15. The business has a 50-day moving average price of $25.64 and a 200 day moving average price of $22.42. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -145.41 and a beta of 0.33.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the sale, the chief operating officer now directly owns 119,911 shares in the company, valued at $3,226,805.01. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,692 shares of company stock worth $2,950,315. Insiders own 54.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wedbush upped their price target on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $33.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.